QuanYu Medical Files for IPO to Expand Its Precision Cloud Radiotherapy Platform Coverage to 50% of Radiotherapy Units Nationwide
In developed countries such as the United States and Japan, the five-year average survival rate for malignant tumors has reached 70%, whereas in China, it has not yet reached half of that level. In the United States, approximately 70%–80% of all cancer patients require radiotherapy. In China, radiotherapy is also one of the optimal treatment methods for cancer patients currently and serves as a crucial means to address the low five-year average survival rate for malignant tumors in the country.Beijing Yuanyu Medical Technology Co., Ltd. is dedicated to developing and providing precise cloud-based radiotherapy systems and services, with the aim of improving survival rates for cancer patients and promoting greater standardization and normalization of oncology diagnosis and treatment in China.VCBeat has provided follow-up coverage on the fact that Quanyu Medical has partnered with 412 medical institutions across China, with its business operations spanning 27 provinces, municipalities, and autonomous regions.
Cheng Zheng, CEO of Quanyu Medical
In China, eight people are diagnosed with cancer every minute, and the incidence and mortality rates of cancer are expected to continue rising over the next decade. Approximately 70% of cancer patients require radiotherapy during their treatment course, and about 40% of cancers can be cured through radiotherapy. These figures underscore the critical role of radiotherapy in the diagnosis and management of tumors.
Survey results from 2015 indicate that the number of institutions providing radiotherapy in China nearly doubled over a 15-year period. The nationwide numbers of radiation oncologists and medical physicists reached 3.10 and 5.32 times their 2001 levels, respectively. In 2015, the ratio of radiation oncologists to medical physicists engaged in radiotherapy was 4.81:1, a significant decrease from 8.26:1 in 2001. These data underscore the pivotal role of medical physicists in the development of high-quality radiotherapy treatment plans.
Global Medical has developed a precision cloud-based radiotherapy operating system that enables better radiotherapy treatment planning through quality control, remote collaboration, physician assistance, and physician training.
Precision Cloud Radiotherapy™ Quality Control System
Global Precision CloudRadiotherapy™The quality control system is built upon the American TG series, as well as national and provincial/municipal quality control standards in China. By integrating local characteristics and equipment configurations, it structures and digitizes radiotherapy data from various hospitals, enabling the collection and oversight of machine and process quality control. The system provides timely alerts, real-time process visibility, comprehensive professional training, and convenient big-data statistical analysis. It offers all-around support and services for radiotherapy in hospitals at all levels.
Precision Cloud Radiotherapy™ Collaborative System
Full-Domain Precision CloudRadiotherapy™Leveraging the mdaccAutoPlan® radiotherapy planning algorithm and TPS fitting, this collaborative system addresses the common challenges of precise target delineation and treatment plan design in radiotherapy through coordinated execution between tertiary and primary care hospitals. It enables access to patient workflow quality control information, online image viewing, follow-up data tracking, and secure transmission of large files, thereby providing patients with a comfortable and convenient medical experience as well as an advanced and innovative treatment model.
Precision Cloud Radiotherapy™ Training System
Global Precision CloudRadiotherapy™Dedicated to comprehensively enhancing the professional competence of radiation therapy practitioners, the training system aggregates high-quality resources, including elite courses from industry leaders and experts, classic domestic and international case studies and academic reports, and videos from major industry conferences. It features exclusive products and services such as the Precision Cloud Radiotherapy™ series of quality control instructional videos. The content covers quality control, technology, maintenance, clinical practice, frontier science, latest developments, equipment application, and management within the field of radiation therapy. Functions such as customized recommendations and interest management ensure personalized user needs are met.
Precision Cloud Radiotherapy™ Research System
The Whole-Region Precision Cloud Radiotherapy™ Research System is dedicated to serving the field of radiotherapy research in China. Relying on advanced oncology radiotherapy institutions, it aims to assist radiotherapy professionals in conveniently managing patient enrollment for research projects, flexibly controlling workflows, and intelligently linking data from quality control and collaboration systems. This addresses the current disconnect between clinical treatment and academic research among physicians in China. The system comprehensively enhances the academic and research capabilities of radiotherapy professionals, providing substantial and reliable data-driven decision support to improve clinical patient care.
Currently, VCBeat has learned that the market offers solutions targetingDepartment of Radiation OncologyAmong the startups are QuanYu Medical, Lianxin Technology, Shenzhen Yinuo, and Purun Medical. QuanYu Medical’s core advantage lies in its dedicated focus on world-leading precision cloud-based radiotherapy technology, leveraging the globally advanced MD Anderson AutoPlan (mdaccAutoPlan) treatment planning algorithm. The mdaccAutoPlan system is an intelligently designed radiotherapy treatment planning platform built upon years of accumulated big data from tumor treatment plans at The University of Texas MD Anderson Cancer Center. Double-blind testing conducted by oncology experts has demonstrated that this system holds significant clinical application value.
By leveraging advanced technologies such as interoperability, big data, and cloud computing, and combining them with the advantages of comprehensive radiotherapy solutions, Quanyu Medical has developed a series of networked information systems, including Precision Cloud Quality Control and Precision Cloud Collaboration. Meanwhile, the company is actively involved in fields such as oncology radiotherapy, nuclear medicine, and comprehensive medical imaging solutions, providing professional services across four key dimensions: technology, equipment, management, and capital.
The Whole-Area Precision Cloud Radiotherapy™ Operating System, as the company's core product,Based on a cloud-based radiotherapy big database, it is compatible with medical informatics standards such as DICOM-RT and HL7., consisting of four components: the quality control system, the collaboration system, the training system, and the scientific research system.Through this system, managers and users at all levels of radiotherapy-related units can intuitively and comprehensively access the required information, thereby providing objective and accurate guidance for radiotherapy operations.
As of December 2016, a total of 412 institutions had partnered with All-region Healthcare. These included the University of Texas MD Anderson Cancer Center and several renowned cancer hospitals led by the Cancer Hospital of the Chinese Academy of Medical Sciences. Additionally, there were 16 hospitals hosting provincial quality control centers and 396 other hospitals at various levels. The partnership coverage rate reached 30%, spanning 27 provinces, municipalities, and autonomous regions across China.
In terms of technology, Quanyu Medical aims to elevate AutoPlan to the next level, enabling faster coverage of all TPS platforms, while designing more practical tools and automated connectivity features for its Precision Cloud Radiotherapy System. From an operational perspective, the next step is to onboard more clients and deliver enhanced services, such as training programs.Currently, our system services cover 30% of radiotherapy institutions across China. Our next goal is to reach 50%, or even higher.; At the corporate level, the company achieved a slight profit this year and will further expand its revenue and profit next year to lay the groundwork for future operations.
Quanyu Medical’s current profit model primarily revolves around providing radiotherapy customers with comprehensive solutions encompassing software, products, and services. Leveraging CCII’s established expertise in oncology diagnosis and treatment, the company aims to further expand its market presence. Additionally, it offers enhanced collaborative services for the “to-C” segment, generating revenue through these patient-focused collaborative services.This year's revenue has yielded a positive profit.
Since its founding in 2012, the Quanyu team has grown to over 190 members. It includes senior product managers specializing in informatization construction and medical software; development, testing, and operations teams with years of experience in the healthcare industry; dedicated teams of senior physicians and medical physicists; professional teams for medical and radiotherapy software product and content operations; and comprehensive promotion and project implementation teams. Most importantly, it comprises robust R&D and marketing teams.
Last year, Quanyu Healthcare completed its RMB 30 million Series A1 financing round, led by Lian Fund. The company’s Series A2 financing round, amounting to RMB 180 million, was also led by Zhenghe Cixi Capital and Lian Fund.